Telix Pharmaceuticals Limited (TLPPF) Stock: Price, Forecast & Analyst Target
Telix Pharmaceuticals Limited (TLPPF) — price $8.66 (-3.88%), as of the Nov 19, 2026 trading session; market cap $2.94B.
Educational signal · not a buy or sell recommendation · How to read this
Telix Pharmaceuticals Limited · TLPPF
Telix Pharmaceuticals Limited is a biotechnology company specializing in molecularly targeted radiation (MTR) products for cancer and rare diseases.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $8.66 | |
| Change on the day | -3.88% | |
| 52-week range | $5.91 – $13.00 | |
| Market capitalisation | $2.94B | — |
| Price / earnings (trailing) | 92.87 | |
| Shares traded on the day | 1.1K |
Price & events
Other perspectives
Council score for Telix Pharmaceuticals (TLPPF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Telix Pharmaceuticals (TLPPF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Telix Pharmaceuticals Limited (TLPPF) is the company analyzed here. It employs 1,184 people and is led by Christian Behrenbruch. In Q2 FY2026 it reported revenue of $467M and net income of $38M. The market values it at $2.94B.
What do the latest results show for Telix Pharmaceuticals (TLPPF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $467M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $467M | $38M | $0.11 (diluted) |
| Q4 FY2025 | $417M | -$5M | -$0.01 (diluted) |
| Q2 FY2025 | $355M | -$2M | -$0.01 (diluted) |
| Q4 FY2024 | $594M | $38M | $0.11 (diluted) |
What are the financial strengths and risks for Telix Pharmaceuticals (TLPPF)?
Short answer · as of
The distress and quality screens read Altman Z 3.87 · Piotroski F 5. Trailing ratios: ROE 7.4% · ROA 2.7% · current ratio 2.01.
What should you watch next at Telix Pharmaceuticals (TLPPF)?
Short answer · as of
Current published price targets run low $20.00 · high $22.00 · consensus $21.00 · median $21.00 against a quoted price of $8.66 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $20.00 – $22.00
- Consensus target
- $21.00
- Median target
- $21.00
Consensus record · Captured .
Measured against a quoted price of $8.66 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TLPPF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TLPPF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: TLPPF Stock
These answers are editorial: 1 of these 8 answers is drawn from the TLPPF research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is TLPPF a good stock to buy?
Stock Expert AI does not rate TLPPF buy, sell or hold. Telix Pharmaceuticals Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TLPPF stock price today?
The last price recorded for Telix Pharmaceuticals Limited (TLPPF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TLPPF price target?
The analyst consensus price target for Telix Pharmaceuticals Limited (TLPPF), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for TLPPF?
Telix Pharmaceuticals Limited faces several risks, including potential delays in regulatory approvals for its products, which could impact market entry timelines. The company's reliance on successful clinical trial outcomes is critical, as failures could hinder growth prospects.
What are the key factors to evaluate for TLPPF?
Evaluate TLPPF on fundamentals, analyst consensus, and risk factors. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. No dividend yield, indicating a focus on reinvestment into product development and growth. Not financial advice.
How frequently does TLPPF data refresh on this page?
TLPPF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TLPPF's recent stock price performance?
Telix Pharmaceuticals Limited (TLPPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline targeting significant unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TLPPF overvalued or undervalued right now?
The trailing P/E of Telix Pharmaceuticals Limited (TLPPF) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 13 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com